- Home
- KC vs CNTA Comparison
KC vs CNTA Comparison
Compare KC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | CNTA |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | China | United Kingdom |
| Employees | 15225 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KC | CNTA |
|---|---|---|
| Price | $15.35 | $39.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $18.00 | ★ $43.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $30.93 | N/A |
| Revenue Next Year | $20.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.29 | $10.95 |
| 52 Week High | $18.52 | $40.26 |
Technical Indicators
Market Signals| Indicator | KC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 71.70 |
| Support Level | $12.94 | $39.36 |
| Resistance Level | $17.85 | $39.86 |
| Average True Range (ATR) | 0.73 | 0.14 |
| MACD | -0.04 | -0.34 |
| Stochastic Oscillator | 18.13 | 47.52 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.